From Attune Medical receiving FDA 510(k) clearance to Synapse Medical having CE Mark approval, here are 5 medtech stories we missed this week but thought were still worth mentioning. 1. Attune Medical gets FDA 510(k) clearance Attune Medical announced in a Jan. 8 press release that it has received FDA 510(k) clearance for its EnsoETM […]
Lifetech launches post-market LAA device study
LifeTech Scientific said this week it is launching a 3-year post-market surveillance study of its LAmbre left atrial appendage closure system. The Chinese developer said it plans to enroll 500 patients in the study at 30 clinical centers across Europe, Asia and South America. “New devices have been developed to make the procedure even safer and […]
Chinese dev LifeTech wins CE Mark for LAA closure device
Chinese developer LifeTech Scientific said today it won CE Mark approval in the European Union for its LAmbre left atrial appendage closure system, touting it as the 1st Chinese-developed LAA closure system to receive such approval. The LAmbre system is designed for the closure of the LAA percutaneously through a small 8 to 10 Fr […]
Medtronic, Lifetech expand China pacemaker deal
TCT 2013: Docs trade barbs over LAA closure
St. Jude Medical’s Amulet LAA occluder
Medtronic closes strategic investment in LifeTech | Wall Street Beat
Medtronic (NYSE:MDT) said it’s closed a $66 million investment in Chinese medical device company LifeTech Scientific (HK:8122).
Weight loss: ReShape Medical forms up $16M | Wall Street Beat
ReShape Medical reeled in $15.8 million of a hoped-for $21.5 million funding round from a group of 7 unnamed investors, according to a regulatory filing.
The San Clemente, Calif.-based medical device company is developing a non-surgical weight loss device, the ReShape Duo, to treat obese patients. The device is a dual balloon designed to take up space in the stomach to reduce its capacity for food.
Breaking: Medtronic puts more skin in China with $66M investment in LifeTech
Medtronic (NYSE:MDT) further bolstered its footprint in China with a $66.2 million investment into LifeTech Scientific Corp., maker of medical devices for treating cardiovascular disease.
Medtronic purchased a 19% equity interest in LifeTech for about $46.6 million, adding to that a $19.6 million convertible note purchase, representing a total of a more than 26% stake in the Chinese firm.
